# Melasma

Manage melasma as a chronic, relapsing facial pigment disorder: confirm the clinical pattern, exclude inflammatory, drug-related, and dermal pigment mimics, identify hormonal and photic triggers, and use durable photoprotection with topical therapy before cautiously escalating refractory disease.

**Clinical question:** How should clinicians diagnose, treat, and safely escalate management of facial melasma?

Updated: 2026-09-15T23:31:52.849307+00:00

## What matters in practice
- Typical symmetric facial brown-to-gray macules and patches are diagnosed clinically; routine laboratory testing is not indicated unless the presentation suggests an alternative disorder. [12]
- Ask specifically about ultraviolet and visible-light exposure, pregnancy, oral contraceptives, family history, inflammatory facial disease, and pigment-inducing or phototoxic products because each can alter trigger control and the differential. [10][12][16]
- Use rigorous photoprotection as a core treatment rather than an adjunct: ultraviolet and visible light can stimulate pigmentation and aggravate melasma. [10]
- Topical depigmenting therapy is the usual initial pharmacologic strategy; hydroquinone, retinoids, azelaic acid, and topical tranexamic acid may cause irritation or contact dermatitis that can worsen pigmentary disease. [3][19]
- Reserve oral tranexamic acid for severe or refractory disease after individualized thrombotic-risk assessment; it is associated with a low thrombotic-event risk and pigment relapse after discontinuation. [1]
- Do not use Wood lamp depth classification to predict response or choose therapy, particularly in darker phototypes, because findings are inconsistent and may be unreliable. [12][24]

## Confirm melasma clinically and identify presentations that need a different workup

The diagnosis is clinical; the pivotal decision is whether the pattern is truly melasma or a mimic.

Diagnose melasma when acquired, usually symmetric brown-to-gray macules or patches involve sun-exposed facial sites in a compatible setting. Record distribution and severity at baseline; MASI or modified MASI can standardize longitudinal assessment, while MELASQoL can identify clinically meaningful psychosocial burden that warrants more active management. [12][15]

Do not obtain routine laboratory studies for a typical presentation. Instead, take a directed history of pregnancy, oral contraceptive use, family history, ultraviolet and visible-light exposure, tanning exposure, facial inflammation, phototoxic medications or products, and prior topical corticosteroid use. Pregnancy, oral contraceptive use, female sex, family history, and light exposure are established associations or triggers. [10][12][16]

Escalate diagnostic evaluation when pigmentation is asymmetric, sharply circumscribed, blue-gray rather than brown, temporally linked to dermatitis or a drug exposure, or accompanied by scale, erythema, scarring, papules, or other signs of active dermatosis. In these cases, reframe the diagnosis toward post-inflammatory hyperpigmentation, phototoxic dermatitis or phytophotodermatitis, drug-induced pigmentation, lichen planus pigmentosus, erythema dyschromicum perstans, pigmented contact dermatitis, discoid lupus erythematosus, ochronosis, Hori nevus, nevus of Ota, argyria, or macular amyloidosis. [12][16]
- Prior acne, eczema, irritant dermatitis, or a procedure followed by pigment change favors post-inflammatory hyperpigmentation rather than primary melasma. [12][16]
- Blue-gray curvilinear dermoscopic pigmentation supports consideration of ashy dermatosis or nevus of Ota; light-brown reticular pigmentation with follicular sparing can occur with café-au-lait macules or nevus spilus. [13]
- A history of unsupervised topical steroid use plus rosacea-like facial dermatitis should prompt recognition of steroid-induced rosacea-like dermatitis with coexisting melanosis. [13]

*Clinical features that redirect evaluation away from uncomplicated melasma. [12][13][16]*

| Finding | Diagnostic implication | Next action |
| --- | --- | --- |
| Prior inflammatory eruption or procedural injury | Post-inflammatory hyperpigmentation becomes more likely. [12][16] | Identify and suppress the active inflammatory trigger before intensifying pigment-directed therapy. [16] |
| Exposure-linked onset after medication, cosmetic, plant, or topical product | Consider drug-induced pigmentation, phototoxic dermatitis, phytophotodermatitis, or pigmented contact dermatitis. [16] | Review exposures and discontinue the suspected trigger when clinically appropriate. [16] |
| Blue-gray, curvilinear dermoscopic pattern | Consider ashy dermatosis or nevus of Ota rather than routine melasma. [13] | Reassess diagnosis; use selective histopathology when the clinical distinction remains uncertain. [12] |
| Scale, erythema, scarring, or other active facial lesions | Consider inflammatory dermatoses including discoid lupus erythematosus or lichen planus pigmentosus. [16] | Evaluate and treat the primary dermatosis; biopsy selectively if morphology is not diagnostic. [12][16] |

## Use dermoscopy selectively; do not let Wood lamp depth determine treatment

Bedside devices can support pattern recognition but should not replace clinical diagnosis.

Dermoscopy can support the diagnosis and characterize pigment and vascular patterns. Reported epidermal-pattern findings include a brown reticuloglobular network; mixed patterns may show patchy brown reticuloglobular pigmentation with gray areas or granules; dermal-pattern descriptions include brown-gray reticuloglobular pigmentation, gray granules, arcuate or honeycomb structures, and perifollicular pigmentation. [24]

Wood lamp may accentuate epidermal pigmentation, but do not use epidermal, dermal, or mixed Wood lamp classification to predict prognosis or select therapy. Findings are inconsistent, particularly in darker phototypes, and Wood lamp evaluation is not suitable for Fitzpatrick skin types V and VI in one comparative study. [12][24]

Consider reflectance confocal microscopy or other advanced imaging only when available and when a noninvasive diagnostic question remains after examination; reflectance confocal microscopy can demonstrate activated melanocytes, melanophages, and solar elastosis. These techniques do not replace selective biopsy for persistent diagnostic uncertainty or concern for another disorder. [16][12]
- Perform Wood lamp examination in a darkened setting and interpret it as an adjunct, not a therapeutic stratifier. [18][12]
- Remove makeup and cosmetics before imaging or photographic assessment to reduce artifact. [14]
- Use standardized clinical photography and the same severity instrument at follow-up when measuring response rather than relying on recollection alone. [15]

*Practical role of common melasma assessment tools. [12][15][24]*

| Tool | Useful contribution | Important limitation |
| --- | --- | --- |
| Clinical examination | Establishes the diagnosis, distribution, triggers, and competing differential diagnoses. [12] | Requires reassessment when morphology or course is atypical. [12][16] |
| Dermoscopy | Can document reticular, gray granular, and vascular features and assist with facial melanosis differentials. [13][24] | Pattern descriptions support but do not independently establish diagnosis. [13][24] |
| Wood lamp | May accentuate epidermal pigment. [16][24] | Depth classification is inconsistent, should not guide treatment, and is limited in darker skin types. [12][24] |
| MASI or modified MASI | Standardizes clinical severity tracking across visits and studies. [15] | Does not itself identify the cause of facial pigmentation. [15] |

## Control photic and hormonal drivers before escalating pigment-directed therapy

Recurrence is expected when ongoing triggers and barrier injury are not addressed.

Make broad photoprotection a nonnegotiable component of every regimen. Ultraviolet radiation is a major driver of melasma, and visible light can also stimulate pigmentation; therefore, treatment plans should explicitly address both exposures rather than relying on depigmenting medications alone. [10]

Review whether pregnancy or hormonal contraception temporally correlates with onset or worsening. These associations do not establish that a hormonal therapy must be stopped, but they justify counseling that persistent exposure may complicate pigment control and should be considered alongside contraceptive and reproductive priorities. [12][16]

Choose a topical regimen that the patient can tolerate consistently. Hydroquinone, retinoids, azelaic acid, and topical tranexamic acid are recognized topical options, but hydroquinone, retinoic acid, and azelaic acid can cause irritation or contact dermatitis. Reduce irritant burden and support the skin barrier if treatment produces inflammation, because inflammation is itself a contributor to hyperpigmentation. [3][19]

Set expectations at initiation: melasma is chronic and relapsing, responses vary, and no single modality is uniformly effective. Use serial photographs and MASI or modified MASI rather than premature switching based on day-to-day pigment variation. [12][15][19]
- Avoid tanning exposure and review sources of incidental light exposure, including outdoor sun exposure and light-emitting screens, when these correlate with flares. [16]
- Ask about potentially phototoxic skin care, makeup products, and medications, including St. John's wort products. [16]
- If burning, erythema, or eczematous change develops after a topical, stop or simplify the suspected irritant regimen and reassess for contact dermatitis or post-inflammatory hyperpigmentation. [19][16]

### Topical treatment selection

For most patients, begin with photoprotection plus a topical depigmenting regimen rather than oral medication or a procedure. Hydroquinone, retinoids, azelaic acid, and topical tranexamic acid are established options in multimodal care; select among them according to prior response and irritation history because tolerability determines whether therapy can be maintained. [3][19]

Do not equate stronger irritation with better efficacy. In patients who develop irritant or allergic contact dermatitis, prioritize barrier-supportive skin care and a less irritating regimen before adding another active agent, since topical-treatment adverse effects can perpetuate pigmentary change. [19]

*Treatment ladder for melasma, organized by indication and tradeoff. [1][3][19]*

| Clinical situation | Management choice | Key tradeoff or action |
| --- | --- | --- |
| New or uncomplicated melasma | Rigorous ultraviolet and visible-light photoprotection plus topical depigmenting therapy. [10][3] | Monitor for irritation and contact dermatitis from active topicals. [19] |
| Topical intolerance or dermatitis | Reduce or stop the suspected irritating active and reinforce barrier-supportive skin care. [19] | Treat inflammation before escalating depigmenting therapy because inflammatory injury can worsen pigment. [19][16] |
| Persistent severe or refractory disease | Consider oral tranexamic acid as an adjunct after individualized risk assessment. [1] | Counsel regarding low thrombotic-event risk and relapse after discontinuation. [1] |
| Stable disease seeking adjunctive procedures | Consider superficial chemical peel, laser, phototherapy, or microneedling only as an adjunct to ongoing foundational management. [3][6] | Balance potential benefit against procedure-related adverse effects and recurrent disease. [3][10] |

## Reserve oral tranexamic acid and procedures for selected refractory disease

Escalation should follow diagnostic reassessment, trigger control, and optimization of a tolerated topical regimen.

Consider oral tranexamic acid only for severe or refractory melasma as an adjunct to continued photoprotection and topical management. Oral use for melasma is not first-line, and the decision requires individualized assessment of thrombotic risk and counseling that relapse can occur after treatment cessation. [1][19]

A reported procedural practice uses oral tranexamic acid 325 mg twice daily for 3 months in patients with a history of melasma to prevent rebound or exacerbation around a procedure. This is a procedure-specific approach rather than a universal melasma regimen; use requires the same thrombotic-risk consideration and careful reconciliation of patient-specific contraindications. [22][1]

Chemical peels, laser and light-based therapies, and microneedling are adjunctive options for stable or treatment-resistant disease, not substitutes for photoprotection and maintenance topical therapy. Because melasma is recalcitrant and recurrent and patients with skin of color may experience treatment-related adverse effects, procedural selection should emphasize conservative technique, informed consent, and close assessment for inflammatory pigment worsening. [3][10][19]

Reassess the diagnosis before repeated procedures or repeated systemic therapy when pigment becomes more gray, asymmetric, inflammatory, or treatment-resistant. A dermal pigment disorder, medication-associated pigmentation, contact dermatitis, or steroid-related facial dermatitis can produce an apparent treatment failure that will not be corrected by simply increasing pigment-directed treatment intensity. [12][13][16]
- Document baseline pigment severity and photographs before initiating oral tranexamic acid or a procedure so that benefit can be judged objectively. [15]
- Counsel that oral tranexamic acid has a low but clinically consequential thrombotic-event risk. [1]
- Maintain photoprotection after procedural improvement because ultraviolet and visible light remain active pigmentary stimuli. [10]

*Escalation decisions in refractory melasma. [1][3][10][22]*

| Option | When to consider | Decision-limiting issue |
| --- | --- | --- |
| Oral tranexamic acid | Severe or refractory melasma after foundational management has been optimized. [1] | Assess thrombotic risk; counsel on low thrombotic-event risk and relapse after discontinuation. [1] |
| Oral tranexamic acid around a procedure | A reported practice is 325 mg twice daily for 3 months in patients with melasma history to prevent rebound or exacerbation. [22] | This is procedure-context use and requires individualized safety assessment. [22][1] |
| Chemical peel | Adjunctive treatment for stable disease within multimodal care. [3][6] | Procedure-induced injury can complicate management of pigmentary disease; continue photoprotection. [3][10] |
| Laser or light-based therapy | Adjunctive option after counseling in selected patients with persistent disease. [3][6] | Recurrence and adverse effects require conservative patient selection, particularly in skin of color. [10] |
| Microneedling | Adjunctive modality, including approaches intended to enhance topical delivery. [3][23] | Do not use it as a replacement for diagnosis, trigger control, and maintenance therapy. [3][10] |

## Monitor for recurrence, treatment injury, and diagnostic drift

Follow-up should measure both pigment response and treatment-induced inflammation.

At each follow-up, compare standardized photographs and a consistent MASI or modified MASI score with baseline, then ask specifically about pruritus, burning, erythema, scale, new acneiform or rosacea-like change, and treatment adherence. A worsening inflammatory examination should trigger regimen simplification and reassessment for contact dermatitis or another diagnosis rather than automatic escalation. [15][19][13]

When pigment improves, continue trigger control and maintenance-oriented skin care because recurrence is characteristic and photic exposure remains a continuing stimulus. Topical skin care support may reduce adverse effects and can be incorporated into maintenance strategies. [19][10]

Reassess quality-of-life burden with MELASQoL when clinical severity and patient distress diverge. Visible facial pigment may have substantial psychosocial consequences, and patient-reported burden can appropriately influence the choice to intensify, simplify, or defer treatment. [12][15]
- New asymmetry, blue-gray color, scale, scarring, or persistent inflammation is an escalation trigger for renewed differential diagnosis. [12][16]
- Document the exact topical products, cosmetics, and procedures used between visits when apparent relapse follows a new exposure. [16][19]
- Treat melasma as a maintenance problem after improvement, not as a condition cured by a single topical, systemic, or procedural course. [3][19]

*Follow-up findings and the next management decision. [12][15][19]*

| Follow-up finding | Interpretation | Next step |
| --- | --- | --- |
| Improved MASI or modified MASI without inflammation | Clinical response is occurring. [15] | Continue effective photoprotection and tolerated maintenance treatment. [10][19] |
| Burning, erythema, scale, or eczematous eruption | Possible irritant or allergic contact dermatitis from topical therapy. [19] | Simplify or stop the suspected topical active and address barrier injury before escalation. [19] |
| Relapse after improvement | Consistent with chronic, recurrent melasma and ongoing trigger exposure. [12][19] | Review photic, hormonal, product, and adherence factors; restart or optimize tolerated foundational therapy. [10][16] |
| Morphologic change or lack of response despite optimized care | Possible alternative diagnosis or coexisting inflammatory disorder. [12][16] | Repeat focused examination, use dermoscopy as appropriate, and consider selective biopsy. [12][13] |

## References
1. Managing Facial Hyperpigmentation - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/articlepdf/2805524/jamadermatology_kundu_2023_it_230001_1692122310.39866.pdf?resultClick=1
2. Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-26693-8
3. Melasma Treatment Strategies in Skin Health | Dermatology | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/melasma-treatment-strategies-in-skin-health
4. CONSORT 2010 Statement: Updated Guidelines for Reporting ... — annals.org — https://annals.org/aim/article/745807/consort-2010-statement-updated-guidelines-reporting-parallel-group-randomized-trials
5. Preferred Reporting Items for Systematic Reviews and Meta-Analyses — annals.org — https://annals.org/aim/fullarticle/744664/preferred-reporting-items-systematic-reviews-meta-analyses-prisma-statement
6. Comparative effectiveness of acupuncture, fire... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2026/04170/comparative_effectiveness_of_acupuncture,_fire.52.aspx?context=latestarticles
7. Evaluating the robustness of the international... : Journal of the European Academy of Dermatology & Venereology — journals.lww.com — https://journals.lww.com/00042358-202606000-00070
8. Assessing the Safety and Efficacy of Picosecond Alexandrite Lasers ... — journals.lww.com — https://journals.lww.com/00000936-202667030-00003
9. Abstracts : Itch - Ovid — journals.lww.com — https://journals.lww.com/itch/fulltext/2019/11001/abstracts.2.aspx
10. Best practices in the treatment of melasma with a focus on patients with skin of color - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0190962223028505
11. Efficacy and safety of adjuvant topical application of botanicals in the treatment of melasma: A systematic review and meta-analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2405844024041276
12. Melasma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK459271
13. Evaluation of Dermoscopic Features in Facial Melanosis with Wood Lamp Examination — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8824457
14. Quantitative classification of melasma with photoacoustic microscopy: a pilot study - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10624224
15. A Scoping Review on Melasma Treatments and Their Histopathologic Correlates — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12015840
16. Melasma: A Step-by-Step Approach Towards a Multimodal Combination Therapy — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11128260
17. Comparison of Dermoscope and Woods Lamp as A Tool to ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/36226006
18. Wood's Light - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK537193
19. The Application of Skin Care Product in Melasma Treatment - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435474
20. Dermatology World Weekly — www.aad.org — https://www.aad.org/dw/weekly
21. Microneedling combined with irradiated human amniotic gel versus ... — journals.lww.com — https://journals.lww.com/01287624-202609000-00004
22. Oral Tranexamic Acid for Prevention and Treatment... - Ovid — journals.lww.com — https://journals.lww.com/dermatologicsurgery/fulltext/2024/12001/oral_tranexamic_acid_for_prevention_and_treatment.12.aspx
23. Improved clinical efficacy of melasma with combination... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2026/03130/improved_clinical_efficacy_of_melasma_with.23.aspx
24. Comparison of Dermoscope and Woods Lamp as A Tool to Study Melanin Depth in Melasma — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9549552

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.